Jeffrey Jenkins, MD
Pulmonary Disease · Ashland, KYNPI 1396189437
Payments from drug & device makers
Across 366 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$476
- Boehringer Ingelheim$465
- Novartis$389
- Sanofi$359
- Regeneron Healthcare Solutions, Inc.$357
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 148 | $2,453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $476 |
| Boehringer Ingelheim | 25 | $465 |
| Novartis | 19 | $389 |
| Sanofi | 14 | $359 |
| Regeneron Healthcare Solutions, Inc. | 16 | $357 |
| AstraZeneca | 21 | $303 |
| Genentech USA, Inc. | 16 | $286 |
| Mylan Specialty L.p. | 11 | $256 |
| United Therapeutics Corporation | 10 | $183 |
| Electromed, Inc. | 11 | $142 |
| Jazz Pharmaceuticals Inc. | 6 | $120 |
| Johnson & Johnson | 7 | $118 |
| Amgen | 5 | $98 |
| Circassia Inc. | 6 | $98 |
| Viatris Specialty LLC | 3 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Philips North America LLC | 4 | $60 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| AbbVie(2 entities) | 2 | $35 |
| Shire North American Group Inc | 2 | $35 |
| Medical Graphics Corporation | 1 | $34 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $13 |
How this compares
$6,612 in reported general payments places this provider in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 354 | $293,006 |
| Fasenra PenBenralizumab | 30 | $171,217 |
| NucalaMepolizumab | 22 | $80,608 |
| TezspireTezepelumab-Ekko | 11 | $45,207 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $34,663 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $34,048 |
| Spiriva HandihalerTiotropium Bromide | 27 | $19,711 |
| Spiriva RespimatTiotropium Bromide | 17 | $16,105 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $12,832 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $11,971 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 188 | $5,929 |
| Ventolin HfaAlbuterol Sulfate | 36 | $3,124 |
| Roflumilast | 38 | $2,708 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,353 |
| Montelukast Sodium | 278 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $2,453 | $407,662427 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $303 | $79,87148 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $465 | $28,07632 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $67 | $73611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sana GhalibAshland$16K
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- Mena ShehataAshland$11K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.